8-K: Vivani Medical to Initiate First Clinical Study for Novel Obesity Implant in Q4 2024

Vivani Medical plans to begin its first clinical trial for its 6-month GLP-1 implant for obesity treatment in the fourth quarter of 2024.

Summary

• Vivani Medical expects to start its first clinical study for the NPM-115 program in the fourth quarter of 2024.
• The NPM-115 program will evaluate a 6-month GLP-1 implant for treating obesity or overweight patients with related health issues.
• The first study, LIBERATE-1, will be conducted in Australia, pending regulatory clearance.
• LIBERATE-1 will assess the safety, tolerability, and pharmacokinetics of the exenatide implant.
• The study will involve a comparison of the implant with weekly semaglutide and exenatide injections.
• The trial will enroll patients who will be titrated on weekly semaglutide injections for 8 weeks before being randomized to receive a single administration of Vivanis exenatide implant, weekly exenatide injections, or weekly 1 mg semaglutide injections for a 9-week treatment duration.
• The exenatide implant is expected to produce comparable exenatide exposure levels as Bydureon BCise.
• Data from the trial is expected to be available in 2025.
• The company is prioritizing the obesity program over its type 2 diabetes program.
• Vivani intends to use Australian government research and development incentives to offset trial costs.

Sentiment

Score: 7

Explanation: The document is positive due to the progress in the clinical program and the focus on a high-demand market. However, there are risks related to regulatory approvals and funding.

Positives

• The company is moving forward with its obesity program, which is a high-demand market.
• The LIBERATE-1 study is designed to provide clinical validation of the NanoPortal drug delivery technology.
• The use of Australian research and development incentives will help reduce trial costs.
• Clinical data from Australia is acceptable to the FDA and other regulatory authorities.
• The exenatide implant has shown encouraging results in preclinical animal models.

Negatives

• The study is pending regulatory clearance in Australia, which could cause delays.
• The company has a history of losses and needs to access additional capital.
• The company is reprioritizing its programs, which may delay other projects.

Risks

• There are risks related to the development and commercialization of the company's products.
• Delays in the development of products could occur due to laws, regulations, and guidelines.
• There are potential delays in submitting and receiving regulatory clearance or approval to conduct development activities.
• The company faces risks related to the initiation, enrollment, and conduct of planned clinical trials.
• The company's ability to access additional capital or otherwise fund its business is a risk.
• Market conditions and the ability of Cortigent to complete its initial public offering are also risks.

Future Outlook

The company expects to initiate the LIBERATE-1 clinical study in Australia in the fourth quarter of 2024, with data projected to be available in 2025. They also plan to explore higher doses of the exenatide implant in future studies.

Management Comments

• Adam Mendelsohn, Ph.D., Vivanis President and Chief Executive Officer, stated that the company is re-prioritizing the development of its GLP-1 implants to focus on the treatment of obesity and chronic weight management.
• Dr. Mendelsohn noted that the NPM-115 program utilizes the same exenatide implant as NPM-119, and the only difference is the population to be studied.

Industry Context

The announcement comes amid significant medical need and unprecedented market demand for obesity treatments, with GLP-1 drugs like semaglutide (Ozempic/Wegovy) gaining popularity. Vivani's implant technology aims to provide a long-term alternative to injections.

Comparison to Industry Standards

• The company's exenatide implant is being compared to semaglutide injections (Ozempic/Wegovy), a leading treatment in the obesity market.
• The LIBERATE-1 study will compare the implant to both semaglutide and exenatide injections (Bydureon BCise), providing a direct comparison to existing treatments.
• The company's 6-month implant duration is a key differentiator from daily or weekly injections, potentially offering improved patient compliance.
• Other companies in the obesity treatment space include Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro), which are developing and marketing GLP-1 based treatments.

Stakeholder Impact

• Shareholders will be impacted by the progress of the clinical program and the potential for future revenue.
• Employees will be involved in the clinical trial and the development of the product.
• Patients may benefit from a new treatment option for obesity.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will submit an application to a Human Research Ethics Committee in Australia.
• The company will initiate the LIBERATE-1 clinical study in Australia in the fourth quarter of 2024.
• The company will analyze the data from the LIBERATE-1 trial, expected in 2025.
• The company may initiate a subsequent clinical study to explore higher doses of the exenatide implant.

Key Dates

Keywords

GLP-1 implant, obesity, clinical study, NPM-115, exenatide, NanoPortal, weight management, LIBERATE-1, semaglutide, Australia, regulatory clearance